Research programme: vasoactive intestinal peptide antagonists - BayerAlternative Names: JV-1-53
Latest Information Update: 29 Mar 2010
At a glance
- Originator Bayer
- Class Peptides
- Mechanism of Action Vasoactive intestinal polypeptide antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Mar 2010 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 13 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)